Danaher’s recurring-revenue moat and accelerating non-respiratory growth support a $322.18 probability-weighted five-year target, while respiratory normalization and a premium valuation temper near-term upside.
Overview
Danaher is a global life-sciences and diagnostics company spanning Biotechnology, Life Sciences, and Diagnostics, with a razor-and-blade model that generated **81.92% recurring revenue ($20.13 billion)** on FY 2025 sales of $24.57 billion. Its moat combines regulatory switching costs in bioprocessing, proprietary diagnostic cartridges and reagents, leading installed platforms such as Cepheid GeneXpert, and the Danaher Business System. Q3 2026 revenue grew 8.5% to $6.554 billion, with core growth excluding respiratory accelerating to 5.5%; adjusted EPS rose 11.5% to $2.11 and adjusted operating margin expanded 110 basis points to 29.0%. FCF was $1.632 billion for the quarter, and FY 2026 adjusted EPS guidance rose to $8.57–$8.62. The recovery remains uneven: respiratory testing revenue is expected to be about $1.5 billion for 2026, and Life Sciences discovery spending remains soft. At $216, the stock trades at 36.6x trailing P/E and 6.15x sales. **The five-year probability-weighted share-price target is $322.18**, while near-term catalysts include bioprocessing normalization, non-respiratory assay growth, and DBS-driven margin expansion.